Insmed reports additional positive ASPEN data: brensocatib 25 mg slows lung function decline in bronchiectasis

INSMED Inc

Brensocatib 25 mg showed significantly less FEV1 decline vs placebo (38 mL vs -62 mL; p=0.0054) at Week 52.
Brensocatib 25 mg also showed nominally significant FVC preservation (75 mL less decline; p<0.0001).
QOL-B Respiratory Symptom Score improved by 3.8 points with 25 mg dose vs placebo (p=0.0004).
Safety profile favorable; common TEAEs included COVID-19, nasopharyngitis, cough, headache.
Insmed plans to file NDA in Q4 2024; potential U.S. launch mid-2025, Europe/Japan H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.